What do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy?

Oncken, Cheryl; Kranzler, Henry R.

doi:10.1093/ntr/ntp136

Cited by 36 publications

(22 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Primary among them is offering greater incentive values for abstinence throughout the intervention, especially to heavier smokers (Higgins et al, 2009) an approach that has been demonstrated to improve outcomes with incentive-based interventions for illicit drug abuse (Higgins et al, 2007b; Lussier et al, 2006; Silverman et al, 1999). Other strategies such as combining the incentives with a smoking-cessation pharmacotherapy represent viable options to explore as well (Oncken & Kranzler, 2009). …”

Section: Discussionmentioning

confidence: 99%

Examining two different schedules of financial incentives for smoking cessation among pregnant women

Higgins

Washio

Lopez

et al. 2014

Preventive Medicine

View full text Add to dashboard Cite

Objective To examine whether an efficacious voucher-based incentives intervention for decreasing smoking during pregnancy and increasing fetal growth could be improved without increasing costs. The strategy was to redistribute the usual incentives so that higher values were available early in the quit attempt. Method 118 pregnant smokers in greater Burlington, VT (studied 2006–2011) were randomly assigned to the revised (RCV) or usual (CV) schedule of abstinence-contingent vouchers, or to a non-contingent vouchers (NCV) control condition wherein vouchers were provided independent of smoking status. Smoking status was biochemically verified; serial sonographic estimates of fetal growth were obtained at gestational weeks 30–34. Results RCV and CV conditions increased point-prevalence abstinence above NCV levels at early (RCV: 40%, CV: 46%, NCV: 13%, p = .007) and late-pregnancy (RCV: 45%; CV: 36%; NCV, 18%; p = .04) assessments, but abstinence levels did not differ between the RCV and CV conditions. The RCV intervention did not increase fetal growth above control levels while the CV condition did so (p < .05). Conclusion This trial further supports the efficacy of CV for increasing antepartum abstinence and fetal growth, but other strategies (e.g., increasing overall incentive values) will be necessary to improve outcomes further.

show abstract

Section: Discussionmentioning

confidence: 99%

Examining two different schedules of financial incentives for smoking cessation among pregnant women

Higgins

Washio

Lopez

et al. 2014

Preventive Medicine

View full text Add to dashboard Cite

show abstract

“…Although its use during pregnancy is restriced to FDA Category C, up to 30% of physicians have been reported to discuss pharmacotherapy for smoking cessation during pregnancy, with up to 10% of pregnant women reporting use of some form of it [28]. Therefore, the plausibility of bupropion being described to pregnant patients for smoking cessation warrants investigation of its safety.…”

Section: Discussionmentioning

confidence: 99%

Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion

Hemauer¹,

Patrikeeva²,

Wang³

et al. 2010

Biochemical Pharmacology

View full text Add to dashboard Cite

Cigarette smoking during pregnancy is a preventable risk factor associated with maternal and fetal complications. Bupropion is an antidepressant used successfully for smoking cessation in non-pregnant patients. Our goal is to determine whether it could benefit the pregnant patient seeking smoking cessation. The aim of this investigation was to determine the role of human placenta in the disposition of bupropion and its major hepatic metabolite, OH-bupropion. The expression of efflux transporters P-gp and BCRP was determined in placental brush border membrane (n = 200) and revealed a positive correlation (p < 0.05). Bupropion was transported by BCRP (Kt 3 μM, Vmax 30pmol/mg protein/min) and P-gp (Kt 0.5 μM, Vmax 6 pmol/mg protein*min) in placental inside out vesicles (IOVs). OH-bupropion crossed the dually-perfused human placental lobule without undergoing further metabolism, nor was it an efflux substrate of P-gp or BCRP. In conclusion, our data indicate that human placenta actively regulates the disposition of bupropion (via metabolism, active transport), but not its major hepatic metabolite, OH-bupropion.

show abstract

“…On the basis of the paucity of data on the efficacy and safety of existing pharmacotherapies for pregnant smokers, nonpharmacological (behavioral) cessation interventions are recommended as first-line treatment despite their relatively lower efficacy in the general population of smokers (Oncken and Kranzler, 2009). Thus, by elucidating the molecular and neurobehavioral effects of perinatal exposure to cessation medications, preclinical studies can inform the clinical treatment of pregnant smokers.…”

mentioning

confidence: 99%

Preclinical Data Elucidate Molecular and Neural Mechanisms of Perinatal Nicotine Effects on Neurodevelopment and Behavior: Translational Opportunities and Implications

Lerman

2010

Neuropsychopharmacol

View full text Add to dashboard Cite

What do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy?

Cited by 36 publications

References 60 publications

Examining two different schedules of financial incentives for smoking cessation among pregnant women

Examining two different schedules of financial incentives for smoking cessation among pregnant women

Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion

Preclinical Data Elucidate Molecular and Neural Mechanisms of Perinatal Nicotine Effects on Neurodevelopment and Behavior: Translational Opportunities and Implications

Contact Info

Product

Resources

About